NCT00273884已完成2 期
Phase 2 Open-Label Study of Amonafide L-Malate in Combination With Cytarabine in Subjects With Secondary Acute Myeloid Leukemia (AML)
Xanthus Pharmaceuticals, Inc.42 个研究点 分布在 2 个国家目标入组 80 人开始时间: 2005年8月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
- 试验地点
- 42
- 主要终点
- - To determine the rate of complete remission with or without complete hematopoietic recovery (CR + CRi).
研究概览
简要总结
This protocol is designed to assess the safety and efficacy of amonafide in combination with cytarabine in subjects with previously untreated secondary AML.
详细描述
This is a two-stage, open-label, phase 2, multicenter study of amonafide L-malate in combination with standard-dose cytarabine in subjects with secondary AML.
Amonafide is a DNA intercalating agent and inhibitor of topoisomerase II that has been extensively studied in patients with malignant solid tumors. Amonafide has also been studied in patients with AML. In three phase I clinical trials, amonafide demonstrated anti-leukemic activity, both as monotherapy and in combination with cytarabine. This protocol is designed to further assess the safety and efficacy of amonafide in combination with cytarabine in subjects with previously untreated secondary AML.
The duration of the study is approximately 42 months: enrollment approximately 18 months and subject duration up to 24 months
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologic diagnosis of AML (≥20% blasts of myeloid lineage in bone marrow), with FAB classification other than M3, secondary to either:
- •Known and documented exposure to prior leukemogenic chemotherapy or radiotherapy, OR
- •Diagnosis of MDS for ≥3 months prior to study entry (prior BM slides documenting MDS must be available for central pathology review).
- •Age 18 years or older.
- •ECOG performance status ≤
- •No prior induction chemotherapy for AML; at least 4 weeks since completion of prior chemotherapy for MDS. (Subjects with rapidly rising blast count may be enrolled within 4 weeks of prior cytotoxic chemotherapy).
- •Fertile and sexually active men and women must use effective contraception throughout study. Women of childbearing potential must have a negative pregnancy test.
- •LVEF ≥50% by MUGA or ECHO.
- •Adequate renal function: serum creatinine ≤1.5 x ULN.
- •Adequate hepatic function: total serum bilirubin ≤1.5 x ULN as well as serum AST and ALT ≤1.5 x ULN.
- •Subject must be able to participate fully in all aspects of the trial.
- •Subject must give voluntary, written consent and HIPAA authorization (US only).
排除标准
- •Histologic diagnosis of FAB M3 AML (acute promyelocytic leukemia).
- •Clinically active CNS leukemia.
- •Known to be HIV positive.
- •Prior induction chemotherapy for AML.
- •Known active hepatitis B or C or other active liver disease.
- •Any major surgery or radiation therapy within 4 weeks prior to study entry.
- •Prior cytotoxic chemotherapy within 4 weeks prior to study entry.(Subjects with rapidly rising blast count may be enrolled within 4 weeks of prior cytotoxic chemotherapy).
- •Persistent chronic non-hematologic toxicity from prior chemotherapy (other than alopecia) that is > than grade
- •Serious concomitant illness (e.g., active pulmonary infection, unstable angina or myocardial infarction within 3 months of study entry, congestive heart failure ≥AHA class 2, stroke within 3 months prior to study entry, uncontrolled hypertension, uncontrolled diabetes, actively bleeding gastric ulcer, etc.).
- •Women who are pregnant or lactating.
- •History of clinically significant allergic reactions attributed to compounds similar to amonafide or cytarabine.
- •Prior enrollment on this trial.
- •Any other known condition (familial, sociological, or geographic) or behavior (including substance abuse, psychological or psychiatric illness), which in the investigator's opinion would make the subject a poor candidate for this trial.
结局指标
主要结局
- To determine the rate of complete remission with or without complete hematopoietic recovery (CR + CRi).
次要结局
- Determine the median duration of complete remission with or without complete hematopoietic recovery (CR or CRi)
- Determine the proportion of subjects remaining in complete remission (CR +CRi) at 6 months, at 12 months and at 18 months
- Determine the median duration of overall survival (OS)
- Correlate clinical responses and duration of responses with specific cytogenetic abnormalities
- Define the population pharmacokinetic (PK) profile of amonafide and its metabolites when administered as an intravenous infusion daily x 5 days in combination with a standard-dose of cytarabine
- Define the safety profile and confirm the acceptability of amonafide and cytarabine
- Correlate PK exposure of amonafide and acetylation of amonafide with safety and efficacy assessments in individual subjects
研究者
研究点 (42)
Loading locations...
相似试验
Unknown
2 期
A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML)Acute Myeloid LeukemiaNCT01066494Antisoma Research20
已完成
2 期
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)VitiligoNCT04525157Clinuvel Pharmaceuticals Limited21
已完成
2 期
A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)Arterial Ischemic StrokeNCT04962503Clinuvel Pharmaceuticals Limited6
已完成
2 期
Afamelanotide as Adjunctive Therapy in Patients Undergoing Photodynamic Therapy (PDT) Utilising Porfimer SodiumPatients Undergoing Photodynamic Therapy Using Porfimer SodiumNCT04425746Clinuvel Pharmaceuticals Limited16
已完成
2 期
A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung CancerSmall Cell Lung CarcinomaNCT01357395Astex Pharmaceuticals, Inc.23